Reaction Details |
| Report a problem with these data |
Target | Aspartyl/asparaginyl beta-hydroxylase |
---|
Ligand | BDBM25150 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_2018811 (CHEMBL4672389) |
---|
IC50 | 11200±n/a nM |
---|
Citation | Brewitz, L; Tumber, A; Zhang, X; Schofield, CJ Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-?-hydroxylase. Bioorg Med Chem28:0 (2020) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Aspartyl/asparaginyl beta-hydroxylase |
---|
Name: | Aspartyl/asparaginyl beta-hydroxylase |
Synonyms: | 1.14.11.16 | ASP beta-hydroxylase | ASPH | ASPH_HUMAN | Aspartate beta-hydroxylase | Aspartyl/asparaginyl beta-hydroxylase | BAH | Peptide-aspartate beta-dioxygenase |
Type: | PROTEIN |
Mol. Mass.: | 85823.27 |
Organism: | Homo sapiens |
Description: | ChEMBL_120098 |
Residue: | 758 |
Sequence: | MAQRKNAKSSGNSSSSGSGSGSTSAGSSSPGARRETKHGGHKNGRKGGLSGTSFFTWFMV
IALLGVWTSVAVVWFDLVDYEEVLGKLGIYDADGDGDFDVDDAKVLLGLKERSTSEPAVP
PEEAEPHTEPEEQVPVEAEPQNIEDEAKEQIQSLLHEMVHAEHVEGEDLQQEDGPTGEPQ
QEDDEFLMATDVDDRFETLEPEVSHEETEHSYHVEETVSQDCNQDMEEMMSEQENPDSSE
PVVEDERLHHDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVSI
FPVEEQQEVPPETNRKTDDPEQKAKVKKKKPKLLNKFDKTIKAELDAAEKLRKRGKIEEA
VNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK
LSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEV
LSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGN
KEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDE
GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGC
RRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFD
DSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI
|
|
|
BDBM25150 |
---|
n/a |
---|
Name | BDBM25150 |
Synonyms: | (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide | Belinosta | Belinostat | PXD-101 | PXD101 |
Type | Small organic molecule |
Emp. Form. | C15H14N2O4S |
Mol. Mass. | 318.348 |
SMILES | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 |
Structure |
|